• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do

by Truveta Research | Jul 14, 2025 | Research, Research Insights

In 2023, the American Academy of Pediatrics (AAP) released groundbreaking new guidelines recommending early treatment for childhood and adolescent obesity—including the use of medications for weight management in adolescents and cautioning against the common practice...
FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents

FDA-approved anti-obesity GLP-1 RA prescription trends among adolescents

by Truveta Research | Jun 3, 2025 | Research, Research Insights

In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents. Among the 1,265,399 adolescents (aged 12-17 years) in this study, the average rate of first-time AOM semaglutide prescriptions was...
ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

ISPOR 2025: Trends in the prescribing and dispensing of GLP-1 anti-obesity medications among adults with cardiovascular disease

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Karthik Murugiah, MBBS, MHS ⊕Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven,...
ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

ISPOR 2025: Real-world temporal and indication-specific variation in drivers of GLP-1 RA discontinuation 

by Truveta Research | May 14, 2025 | Research, Research Insights

Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD, PhD ⊕Truveta, Inc, Bellevue, WA Side effects were the most common...
GLP-1 RA prescription trends: January 2018 – December 2024

GLP-1 RA prescription trends: January 2018 – December 2024

by Truveta staff | Mar 7, 2025 | Research

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
« Older Entries

Share this


Recent posts

  • Shifting trends in initiation of disease-modifying therapies for multiple sclerosis
  • New AAP guidelines are changing pediatric obesity treatment—but there’s still work to do
  • Truveta Experts: Treatment trends for trigeminal neuralgia

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.AcceptPrivacy notice